Letter: should HCV cirrhotics with high bilirubin or Gilbert's syndrome be excluded from paritaprevir, ombitasvir, or dasabuvir?
- PMID: 27040170
- DOI: 10.1111/apt.13574
Letter: should HCV cirrhotics with high bilirubin or Gilbert's syndrome be excluded from paritaprevir, ombitasvir, or dasabuvir?
Comment in
-
Letter: should HCV cirrhotics with high bilirubin or Gilbert's syndrome be excluded from paritaprevir, ombitasvir, or dasabuvir? Authors' reply.Aliment Pharmacol Ther. 2016 May;43(9):1022-3. doi: 10.1111/apt.13586. Aliment Pharmacol Ther. 2016. PMID: 27040171 No abstract available.
Comment on
-
Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy.Aliment Pharmacol Ther. 2016 Mar;43(6):674-96. doi: 10.1111/apt.13514. Epub 2016 Jan 20. Aliment Pharmacol Ther. 2016. PMID: 26787287 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources